Chagas Disease (American Trypanosomiasis) Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results
Download the sample report @ https://www.pharmaproff.com/request-sample/1056
Chagas disease presents itself in two phases including acute and chronic phase. The initial acute phase lasts for about two months after infection.
Get the detailed analysis @ https://www.pharmaproff.com/report/chagas-diseasetherapeutics-pipeline-analysis
The acute phase represents a high number of parasites circulation in the blood but in most cases the symptoms are absent or mild and unspecific. In less than 50% of people bitten by a triatomine bug, characteristic first visible signs can be a skin lesion or a purplish swelling of the lids of one eye.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1056
During the chronic phase, the parasites are hidden mainly in the heart and digestive muscles. It has been observed that upto 30% of patients suffer from cardiac disorders and up to 10% suffer from digestive (typically enlargement of the esophagus or colon) disorders, neurological disorders or mixed alterations.
The drug candidates of Chagas disease pipeline include, but not limited to, Posaconazole, Fexinidazole, and others. Some of the companies having drugs in the Chagas Disease (American Trypanosomiasis) pipeline includes Bayer AG, Eisai Co., Ltd., GlaxoSmithKline Plc, Merck & Co., Inc., and others.
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Toll-free: +1-888-778-7886 (USA/Canada)
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chagas Disease (American Trypanosomiasis) Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results here
News-ID: 1693414 • Views: 325
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances
More Releases for Chagas
2018 – 2024 Chagas Disease Management Market | Global Industry Report
2018 – 2024 Chagas Disease Management Market | Global Industry Report A Recent Market Study On Chagas Disease And Its Current Trends And Future Insights Chagas disease or American trypanosomiasis is a tropical parasitic disease caused by Trypanosoma cruzi. It is transmitted by kissing bugs or triatomine bugs. It can also be transmitted through blood transfusions, in pregnancy, and organ transplantation. In early stage of the Chagas disease, the symptoms include swollen
Chagas Disease Treatment Market to Surpass US$ 10.29 Mn Threshold by 2025
Chagas disease is a tropical parasitic disease and is endemic in 21 countries in Latin America. Chagas disease can transmitted through blood transfusion, organ transplantation, as well as congenital and oral transmissions. Chagas disease is endemic to Latin America, however, in the recent past, there is a rise in global incidence of Chagas disease due to the migration of Latin American people to other countries. According to data published by
Chagas Disease Treatment Market - Insights
Chagas disease is an endemic in 21 Latin American countries caused by kinetoplastid protozoan parasite, Trypanosoma cruzi, primarily transmitted by large, blood-sucking reduviid insects widely known as 'the kissing bugs'. Moreover, the disease can be transferred through other means such as blood transfusion, organ transplantation, as well as congenital and oral transmissions. The recent past has witnessed spread of Chagas disease to developed economies such as Europe and North America,
Chagas Disease Treatment Market - Insights, Trends, Outlook, and Opportunity Ana …
In 2017, Food and Drug Administration (FDA) approved benznidazole for children suffering from Chagas, in the age group of 2 to 12 years. This is the first approved safe and effective therapeutic for Chagas in the U.S. FDA granted benznidazole priority review and orphan product designation, as it is a rare disease and there have been no approved drugs for its treatment in the U.S. This approval is expected to
Chagas Disease Treatment Market - Insights, Analysis, Size, Trends and Forecast, …
American trypanosomiasis also known as Chagas disease is caused by the parasite Trypanosoma cruzi (T.cruzi), which is transmitted by the bite of triatomine bugs. The parasites hide during the day time and become active at night and feed on human blood. T. cruzi can also be transmitted by food contaminated with the parasite, blood transfusion, transmission from infected mother to newborn during gestational period, organ transplant, and laboratory accidents. Its
Chagas Disease (American Trypanosomiasis) Market, Growth, Sales -Pipeline Review …
To Understand the pharmaceutical Industry Status worldwide, Market Research Hub (MRH) has included the latest Forecast report titled “Chagas Disease (American Trypanosomiasis)-Pipeline Review, H2 2017” to its vast database. This study offers data about the prime regions operating in the pharmaceutical sector, along with their production, consumption, revenue and market share details. Further, the intelligent report also anticipates that the market would grow at a constructive CAGR until 2022. Request For